MCID: OLG002
MIFTS: 55

Oligodendroglioma

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Oligodendroglioma

MalaCards integrated aliases for Oligodendroglioma:

Name: Oligodendroglioma 12 50 56 29 52 42 14 69
Oligodendroglial Neoplasm 12 69
Well Differentiated Oligodendroglioma 69
Oligodendroglial Tumors 52
Oligodendroglial Tumor 12

Characteristics:

Orphanet epidemiological data:

56
oligodendroglioma
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3181
MeSH 42 D009837
NCIt 47 C6960
Orphanet 56 ORPHA251627
UMLS via Orphanet 70 C0028945
ICD10 via Orphanet 34 C71.9

Summaries for Oligodendroglioma

NIH Rare Diseases : 50 oligodendrogliomas are brain tumors arising from oligodendrocytes, a type of cell that makes up the supportive (glial) tissue of the brain. they can be low-grade (grade ii) or high-grade (grade iii, also called anaplastic). while they can be found anywhere within the cerebral hemisphere, they are most common in the frontal and temporal lobes. they are generally soft, grayish-pink tumors that often contain mineral deposits (calcifications), areas of hemorrhage, and/or cysts. they tend to grow slowly and may be present for many years before they are diagnosed. common symptoms include seizures, headaches and changes in personality. other symptoms vary by the size and location of the tumor. the exact cause of opigodendrogliomas is unknown. some appear to have a chromosome abnormality involving loss of chromosomes 1p and 19q. treatment generally involves surgical removal of the tumor followed by radiation therapy and/or chemotherapy. recurrent tumors may need additional surgery, radiation and chemotherapy. last updated: 8/8/2016

MalaCards based summary : Oligodendroglioma, also known as oligodendroglial neoplasm, is related to anaplastic oligodendroglioma and mixed oligodendroglioma-astrocytoma. An important gene associated with Oligodendroglioma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial), and among its related pathways/superpathways are Neuroscience and HTLV-I infection. The drugs Carmustine and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and temporal lobe, and related phenotypes are Decreased viability in esophageal squamous lineage and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 72 Oligodendrogliomas are a type of glioma that are believed to originate from the oligodendrocytes of the... more...

Related Diseases for Oligodendroglioma

Diseases in the Oligodendroglioma family:

Adult Oligodendroglioma

Diseases related to Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 265)
id Related Disease Score Top Affiliating Genes
1 anaplastic oligodendroglioma 34.6 GFAP PTEN SYP
2 mixed oligodendroglioma-astrocytoma 33.9 IDH1 IDH2 TP53
3 adult oligodendroglioma 33.6 GFAP IDH1 OLIG2 SYP TP73
4 childhood oligodendroglioma 33.4 CDKN2A PCNA TP53
5 glioblastoma 3 31.2 ENO2 GFAP MGMT SYP TP53 TP73
6 endotheliitis 30.6 ENO2 MBP
7 dysembryoplastic neuroepithelial tumor 30.4 EGFR ENO2 TP53
8 central nervous system disease 29.9 ENO2 GFAP SYP TP53
9 corpus callosum oligodendroglioma 12.0
10 spinal cord oligodendroglioma 11.9
11 brain oligodendroglioma 11.9
12 mixed astrocytoma-ependymoma-oligodendroglioma 11.7
13 glioma susceptibility 1 11.4
14 glioma 11.2
15 optic disk drusen 11.0 IDH1 IDH2
16 2q31.1 microdeletion syndrome 11.0 ENO2 SYP
17 nemaline myopathy 10.9 IDH1 IDH2
18 devriendt syndrome 10.9 GFAP SYP
19 endolymphatic sac tumor 10.9 IDH1 IDH2
20 early myoclonic encephalopathy 10.9 IDH1 IDH2 PTEN
21 hypogonadotropic hypogonadism-frontoparietal alopecia syndrome 10.9 GFAP IDH1 SYP
22 ovarian mucinous cystadenofibroma 10.9 GFAP IDH2 PTEN
23 dystonia 10.9 GFAP SYP
24 spinal cord ependymoma 10.9 GFAP SYP
25 adenofibroma 10.9 GFAP IDH1 SYP
26 epidermal appendage tumor 10.9 GFAP PTEN SYP
27 juxtacortical chondrosarcoma 10.9 CDKN2A IDH1 IDH2
28 papillary glioneuronal tumor 10.9 GFAP IDH1 SYP
29 bannayan-riley-ruvalcaba syndrome 10.9 EGFR PTEN
30 fallopian tube papillary adenocarcinoma 10.9 IDH1 IDH2 SYP
31 macrocystic neurilemmoma 10.9 GFAP IDH1 SYP
32 chilaiditi syndrome 10.8 GFAP MBP SYP
33 brain stem ependymoma 10.8 GFAP OLIG2 SYP
34 pleuropneumonia 10.8 CDKN2A MBP
35 omphalomesenteric cyst 10.8 GFAP IDH2 MGMT
36 paranasal sinus cancer 10.8 ENO2 SYP
37 ampulla of vater small cell carcinoma 10.8 ENO2 SYP
38 meningitis and encephalitis 10.8 ENO2 GFAP
39 pancoast tumor 10.8 GFAP TP53
40 glioma susceptibility 9 10.8
41 glioma susceptibility 2 10.8
42 cauda equina intradural extramedullary astrocytoma 10.8 ENO2 GFAP SYP
43 situs inversus totalis with cystic dysplasia of kidneys and pancreas 10.8 ENO2 SYP
44 cauda equina neoplasm 10.8 ENO2 GFAP SYP
45 axonal neuropathy 10.8 ENO2 GFAP SYP
46 brain stem astrocytic neoplasm 10.8 GFAP TP53
47 malignant granular cell myoblastoma 10.8 ENO2 GFAP SYP
48 sudden sensorineural hearing loss 10.8 ENO2 GFAP SYP
49 pituitary dwarfism with large sella turcica 10.8 ENO2 GFAP SYP
50 pediatric ependymoma 10.7 ENO2 GFAP SYP

Graphical network of the top 20 diseases related to Oligodendroglioma:



Diseases related to Oligodendroglioma

Symptoms & Phenotypes for Oligodendroglioma

GenomeRNAi Phenotypes related to Oligodendroglioma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.9 TP53 CDKN2A CDKN2C CIC GFAP IDH1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 TP53 TP73 CDKN2A CIC NKX2-2 PCNA
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 TP73 CDKN2A CIC NKX2-2 PCNA POT1
4 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 CIC MGMT PCNA POT1 TP53 TP73

MGI Mouse Phenotypes related to Oligodendroglioma:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.34 CDKN2A CDKN2C CIC EGFR ENO2 GFAP
2 behavior/neurological MP:0005386 10.31 CIC ENO2 GFAP MBP OLIG1 OLIG2
3 mortality/aging MP:0010768 10.3 PTEN TP53 TP73 UGT8 CDKN2A CDKN2C
4 cellular MP:0005384 10.26 CDKN2A CDKN2C EGFR ENO2 GFAP MBP
5 immune system MP:0005387 10.14 MBP PCNA PTEN TP53 TP73 UGT8
6 nervous system MP:0003631 10.13 OLIG2 PTEN SYP TP53 TP73 UGT8
7 endocrine/exocrine gland MP:0005379 10.11 CDKN2A CDKN2C EGFR MGMT NKX2-2 PCNA
8 neoplasm MP:0002006 9.97 CDKN2A CDKN2C EGFR IDH2 MGMT OLIG2
9 reproductive system MP:0005389 9.81 CDKN2A CDKN2C EGFR MBP NKX2-2 PCNA
10 respiratory system MP:0005388 9.7 CDKN2A CDKN2C CIC EGFR ENO2 IDH1
11 vision/eye MP:0005391 9.23 OLIG2 PTEN TP53 TP73 CDKN2A EGFR

Drugs & Therapeutics for Oligodendroglioma

Drugs for Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 358)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved Phase 3,Phase 1,Phase 2 154-93-8 2578
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
3
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
6
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
7
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
8
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
9
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
10 Thiotepa Approved Phase 3,Phase 2,Phase 1 52-24-4 5453
11
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
12
Lomustine Approved Phase 3,Phase 2,Phase 1 13010-47-4 3950
13
Procarbazine Approved Phase 3,Phase 2,Phase 1 671-16-9 4915
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
16
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
17
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
18
Ondansetron Approved Phase 3 99614-02-5 4595
19
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
20
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
21
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
22
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
23
Isotretinoin Approved Phase 3,Phase 1 4759-48-2 5538 5282379
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
25
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
26
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538
27 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
28 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antimitotic Agents Phase 3,Phase 2,Phase 1
30 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
31 Antimetabolites Phase 3,Phase 2,Phase 1
32 Antimetabolites, Antineoplastic Phase 3,Phase 2
33 Antirheumatic Agents Phase 3,Phase 2,Phase 1
34 Dermatologic Agents Phase 3,Phase 1,Phase 2
35 Etoposide phosphate Phase 3,Phase 2,Phase 1
36 Folic Acid Antagonists Phase 3,Phase 2
37 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
38 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
39 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
40 Vitamin B Complex Phase 3,Phase 2,Phase 1
41 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
42 Liver Extracts Phase 3,Phase 2,Phase 1
43 Keratolytic Agents Phase 3,Phase 1,Phase 2
44 Adjuvants, Anesthesia Phase 3
45 Analgesics Phase 3,Phase 2,Phase 1
46 Analgesics, Opioid Phase 3
47 Anesthetics Phase 3,Phase 1
48 Anesthetics, General Phase 3
49 Anesthetics, Intravenous Phase 3
50 Narcotics Phase 3

Interventional clinical trials:

(show top 50) (show all 363)

id Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
3 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
4 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
5 Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
6 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
7 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
10 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
11 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
12 Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
13 Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Recruiting NCT00978458 Phase 3 temozolomide
14 Phase III Trial of Anaplastic Glioma Without 1p/19q LOH Active, not recruiting NCT00626990 Phase 3 temozolomide
15 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Active, not recruiting NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
16 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3 Temozolomide
17 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
18 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
19 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
20 Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma Unknown status NCT00003472 Phase 2 antineoplaston A10;antineoplaston AS2-1
21 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
22 A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas Unknown status NCT02209428 Phase 2 Temozolomide
23 A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma Unknown status NCT00683761 Phase 1, Phase 2 131I-TM601
24 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2 temozolomide
25 Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma Unknown status NCT00360945 Phase 2 cisplatin;temozolomide
26 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
27 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
28 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
29 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
30 Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
31 Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
32 Temozolomide in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00003465 Phase 2 temozolomide
33 Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma Completed NCT00004024 Phase 2
34 Topotecan in Treating Patients With Recurrent Brain Tumors Completed NCT00003372 Phase 2 topotecan hydrochloride
35 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma Completed NCT01663012 Phase 2 Etirinotecan pegol
36 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
37 Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
38 Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma Completed NCT00823459 Phase 2 RAD001
39 Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) Completed NCT00615927 Phase 2 Imatinib Mesylate & Hydroxyurea
40 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003304 Phase 2 temozolomide
41 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
42 Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors Completed NCT00012038 Phase 1, Phase 2 irofulven
43 Procarbazine in Treating Patients With Recurrent Brain Tumor Completed NCT00004004 Phase 1, Phase 2 procarbazine hydrochloride
44 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003731 Phase 2 temozolomide
45 Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma Completed NCT00575887 Phase 2 Temozolomide
46 The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) Completed NCT00392171 Phase 2 Temozolomide
47 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin
48 A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Completed NCT00565721 Phase 2 Fluciclatide Injection - (AH111585 (F18))
49 BIBF 1120 for Recurrent High-Grade Gliomas Completed NCT01380782 Phase 2 BIBF 1120
50 FR901228 in Treating Patients With Recurrent High-Grade Gliomas Completed NCT00085540 Phase 1, Phase 2 depsipeptide

Search NIH Clinical Center for Oligodendroglioma

Cochrane evidence based reviews: oligodendroglioma

Genetic Tests for Oligodendroglioma

Genetic tests related to Oligodendroglioma:

id Genetic test Affiliating Genes
1 Oligodendroglioma 29

Anatomical Context for Oligodendroglioma

MalaCards organs/tissues related to Oligodendroglioma:

39
Brain, Spinal Cord, Temporal Lobe, Bone, Bone Marrow, T Cells, Endothelial

Publications for Oligodendroglioma

Articles related to Oligodendroglioma:

(show top 50) (show all 704)
id Title Authors Year
1
Diffuse Infiltrating Oligodendroglioma and Astrocytoma. ( 28640702 )
2017
2
A Case of Congenital Brainstem Oligodendroglioma: Pathology Findings and Review of the Literature. ( 28815096 )
2017
3
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. ( 28472509 )
2017
4
Vascular Endothelial Growth Factor as an Angiogenic Marker in Malignant Astrocytoma and Oligodendroglioma: An Indian Scenario. ( 28384867 )
2017
5
Characterization of brain tumours with spin-spin relaxation: pilot case study reveals unique T 2 distribution profiles of glioblastoma, oligodendroglioma and meningioma. ( 28894952 )
2017
6
Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI. ( 28126746 )
2017
7
Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted. ( 28812310 )
2017
8
CNS cancer: Tracing stem cells in oligodendroglioma. ( 27874063 )
2017
9
Multimodal (18)F-Fluciclovine PET/MRI and Ultrasound-Guided Neurosurgery of an Anaplastic Oligodendroglioma. ( 28844925 )
2017
10
Osteosclerosis Secondary to Metastatic Oligodendroglioma. ( 28435646 )
2017
11
Pinpointing Cancer Stem Cells in Oligodendroglioma. ( 27864226 )
2017
12
Clinical, radiological, pathological and prognostic aspects of intraventricular oligodendroglioma: comparison with central neurocytoma. ( 28900829 )
2017
13
Metastatic grade III oligodendroglioma revealed by refractory thrombocytopenia. ( 28737366 )
2017
14
Synchronous gemistocytic astrocytoma IDH-mutant and oligodendroglioma IDH-mutant and 1p/19q-codeleted in a patient with CCDC26 polymorphism. ( 28550371 )
2017
15
Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis. ( 28498059 )
2017
16
Pica in a Child with Anterior Cingulate Gyrus Oligodendroglioma: Case Report. ( 28704833 )
2017
17
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. ( 28696020 )
2017
18
Vessel morphometric parameters-correlation with histologic grade and VEGF expression in oligodendroglioma. ( 28469969 )
2017
19
IMAGING DIAGNOSIS -ANTEMORTEM DETECTION OF OLIGODENDROGLIOMA "CEREBROSPINAL FLUID DROP METASTASES" IN A DOG BY SERIAL MAGNETIC RESONANCE IMAGING. ( 28176389 )
2017
20
Cerebellar Cystic Oligodendroglioma in a Young Adult. ( 28694642 )
2017
21
Genetic landscape of extreme responders with anaplastic oligodendroglioma. ( 28388591 )
2017
22
Bone Marrow Metastases from a 1p/19q Co-deleted Oligodendroglioma - A Case Report. ( 27466523 )
2016
23
Application of diffusion-weighted imaging and dynamic susceptibility contrast perfusion-weighted imaging for ganglioglioma in adults: Comparison study with oligodendroglioma. ( 27502573 )
2016
24
Case 38-2016. A 52-Year-Old Woman with Recurrent Oligodendroglioma. ( 27974037 )
2016
25
World Health Organization Grade II Oligodendroglioma Occurring after Successful Treatment for Childhood Acute Lymphoblastic Leukemia. ( 27867928 )
2016
26
Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma. ( 26722084 )
2016
27
Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma. ( 27251883 )
2016
28
Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups. ( 26757882 )
2016
29
Utilization and impact of adjuvant therapy in anaplastic oligodendroglioma: an analysis on 1692 patients. ( 27401158 )
2016
30
High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma. ( 26960282 )
2016
31
Low-grade and anaplastic oligodendroglioma. ( 26948366 )
2016
32
IMAGING DIAGNOSIS-MAGNETIC RESONANCE IMAGING FEATURES OF A MULTIFOCAL OLIGODENDROGLIOMA IN THE SPINAL CORD AND BRAIN OF A DOG. ( 27490488 )
2016
33
Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. ( 27806376 )
2016
34
Oligodendroglial cell proliferation arising in an ovarian mature cystic teratoma. Clinicopathological, inmunohistochemical, and ultrastructural study of a case that may represent an oligodendroglioma. ( 28029275 )
2016
35
Granular cells in oligodendroglioma suggest a neoplastic change rather than a reactive phenomenon: case report with molecular characterisation. ( 27738816 )
2016
36
Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences with Adult Counterparts and Other Pediatric Gliomas. ( 26206478 )
2016
37
Radiological imaging features of glioblastoma with oligodendroglioma component: a comparison with conventional glioblastoma. ( 27900202 )
2016
38
Synchronous thymoma and oligodendroglioma: A rare association. ( 26957188 )
2016
39
Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. ( 27812792 )
2016
40
Sarcoma-like tumor originating from oligodendroglioma. ( 27333891 )
2016
41
Cytokine-induced release of ceramide-enriched exosomes as a mediator of cell death signaling in an oligodendroglioma cell line. ( 27623848 )
2016
42
The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients. ( 27651340 )
2016
43
Papilloedema secondary to oligodendroglioma. ( 27489047 )
2016
44
A rare presentation of anaplastic oligodendroglioma metastatic to bone marrow, mimicking blast cells. ( 27302043 )
2016
45
Glioblastoma with oligodendroglioma component in a ewe. ( 27154317 )
2016
46
Imaging of oligodendroglioma. ( 26849038 )
2016
47
Racial disparities in anaplastic oligodendroglioma: An analysis on 1643 patients. ( 28024733 )
2016
48
Tumor cell-specific chromosomal abnormality in the vascular endothelial cells of anaplastic oligodendroglioma. ( 26771849 )
2016
49
Oligodendroglioma metastasis to the bone marrow mimicking multiple myeloma: A case report. ( 27347150 )
2016
50
Molecular characterization reveals NF1 deletions and FGFR1-activating mutations in a pediatric spinal oligodendroglioma. ( 27862886 )
2016

Variations for Oligodendroglioma

ClinVar genetic disease variations for Oligodendroglioma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388

Cosmic variations for Oligodendroglioma:

9 (show top 50) (show all 2110)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10790 TP53 central nervous system,brain,glioma,anaplastic c.455C>T p.P152L 5
2 COSM44829 TP53 central nervous system,brain,glioma,anaplastic c.403T>G p.C135G 5
3 COSM10659 TP53 central nervous system,brain,glioma,anaplastic c.817C>T p.R273C 5
4 COSM10648 TP53 central nervous system,brain,glioma,anaplastic c.524G>A p.R175H 5
5 COSM10654 TP53 central nervous system,brain,glioma,anaplastic c.637C>T p.R213* 5
6 COSM44570 TP53 central nervous system,brain,glioma,anaplastic c.332T>G p.L111R 5
7 COSM43742 TP53 central nervous system,brain,glioma,anaplastic c.419C>T p.T140I 5
8 COSM43679 TP53 central nervous system,brain,glioma,anaplastic c.531C>T p.P177P 5
9 COSM44262 TP53 central nervous system,brain,glioma,anaplastic c.808T>C p.F270L 5
10 COSM10726 TP53 central nervous system,brain,glioma,anaplastic c.856G>A p.E286K 5
11 COSM43748 TP53 central nervous system,brain,glioma,anaplastic c.783T>C p.S261S 5
12 COSM44606 TP53 central nervous system,brain,glioma,anaplastic c.665C>T p.P222L 5
13 COSM11090 TP53 central nervous system,brain,glioma,anaplastic c.541C>T p.R181C 5
14 COSM43765 TP53 central nervous system,brain,glioma,anaplastic c.727A>C p.M243L 5
15 COSM11133 TP53 central nervous system,brain,glioma,anaplastic c.725G>C p.C242S 5
16 COSM43545 TP53 central nervous system,brain,glioma,anaplastic c.503A>G p.H168R 5
17 COSM11564 TP53 central nervous system,brain,glioma,anaplastic c.742C>G p.R248G 5
18 COSM11198 TP53 central nervous system,brain,glioma,anaplastic c.785G>T p.G262V 5
19 COSM10651 TP53 central nervous system,brain,glioma,anaplastic c.530C>G p.P177R 5
20 COSM10768 TP53 central nervous system,brain,glioma,anaplastic c.535C>T p.H179Y 5
21 COSM44327 TP53 central nervous system,brain,glioma,anaplastic c.518T>C p.V173A 5
22 COSM10891 TP53 central nervous system,brain,glioma,anaplastic c.814G>A p.V272M 5
23 COSM46287 TP53 central nervous system,brain,glioma,anaplastic c.557A>G p.D186G 5
24 COSM10645 TP53 central nervous system,brain,glioma,anaplastic c.527G>T p.C176F 5
25 COSM43745 TP53 central nervous system,brain,glioma,anaplastic c.918A>T p.R306R 5
26 COSM10777 TP53 central nervous system,brain,glioma,anaplastic c.715A>G p.N239D 5
27 COSM10750 TP53 central nervous system,brain,glioma,anaplastic c.490A>T p.K164* 5
28 COSM6906 TP53 central nervous system,brain,glioma,anaplastic c.672+1G>A p.? 5
29 COSM43747 TP53 central nervous system,brain,glioma,anaplastic c.872A>G p.K291R 5
30 COSM43843 TP53 central nervous system,brain,glioma,anaplastic c.817C>G p.R273G 5
31 COSM11196 TP53 central nervous system,brain,glioma,anaplastic c.734G>T p.G245V 5
32 COSM44623 TP53 central nervous system,brain,glioma,anaplastic c.487T>A p.Y163N 5
33 COSM43973 TP53 central nervous system,brain,glioma,anaplastic c.718A>G p.S240G 5
34 COSM44910 TP53 central nervous system,brain,glioma,anaplastic c.403T>A p.C135S 5
35 COSM43743 TP53 central nervous system,brain,glioma,anaplastic c.914A>G p.K305R 5
36 COSM5039 PTEN central nervous system,brain,glioma,anaplastic c.518G>A p.R173H 5
37 COSM5152 PTEN central nervous system,brain,glioma,anaplastic c.388C>T p.R130* 5
38 COSM5335 PTEN central nervous system,brain,glioma,anaplastic c.1211G>C p.*404S 5
39 COSM5033 PTEN central nervous system,brain,glioma,anaplastic c.389G>A p.R130Q 5
40 COSM5113 PTEN central nervous system,brain,glioma,anaplastic c.314G>A p.C105Y 5
41 COSM5110 PTEN central nervous system,brain,glioma,anaplastic c.632G>A p.C211Y 5
42 COSM5211 PTEN central nervous system,brain,glioma,anaplastic c.376G>C p.A126P 5
43 COSM5230 PTEN central nervous system,brain,glioma,anaplastic c.758T>A p.I253N 5
44 COSM5298 PTEN central nervous system,brain,glioma,anaplastic c.19G>T p.E7* 5
45 COSM5187 PTEN central nervous system,brain,glioma,anaplastic c.392C>A p.T131N 5
46 COSM5267 PTEN central nervous system,brain,glioma,anaplastic c.820T>G p.W274G 5
47 COSM5232 PTEN central nervous system,brain,glioma,anaplastic c.44G>T p.R15I 5
48 COSM249141 PIK3CA central nervous system,brain,glioma,anaplastic c.3023C>G p.S1008C 5
49 COSM249139 PIK3CA central nervous system,brain,glioma,anaplastic c.3013A>G p.M1005V 5
50 COSM767 PIK3CA central nervous system,brain,glioma,anaplastic c.1637A>C p.Q546P 5

Copy number variations for Oligodendroglioma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13342 1 1 124300000 Loss Oligodendroglial tumors
2 42816 10 40300000 135374737 Loss Oligodendroglial tumors
3 119741 18 16100000 76117153 Loss Oligodendroglial tumors
4 124095 19 1 28500000 Gain Oligodendroglial tumors
5 127178 19 28500000 63811651 Loss Oligodendroglial tumors
6 187538 4 50700000 191273063 Loss Oligodendroglial tumors
7 217108 7 1 59100000 Gain Oligodendroglial tumors
8 226562 7 59100000 158821424 Gain Oligodendroglial tumors
9 244959 9 1 51800000 Loss Oligodendroglial tumors

Expression for Oligodendroglioma

Search GEO for disease gene expression data for Oligodendroglioma.

Pathways for Oligodendroglioma

GO Terms for Oligodendroglioma

Biological processes related to Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 cell cycle arrest GO:0007050 9.73 CDKN2A CDKN2C TP53 TP73
2 negative regulation of neuron differentiation GO:0045665 9.67 NKX2-2 OLIG2 TP73
3 cellular response to UV GO:0034644 9.65 PCNA TP53 TP73
4 replicative senescence GO:0090399 9.55 CDKN2A TP53
5 DNA ligation GO:0006266 9.54 MGMT PCNA
6 negative regulation of telomerase activity GO:0051974 9.52 POT1 TP53
7 mitotic G1 DNA damage checkpoint GO:0031571 9.51 TP53 TP73
8 oligodendrocyte differentiation GO:0048709 9.5 CDKN2C OLIG1 OLIG2
9 isocitrate metabolic process GO:0006102 9.46 IDH1 IDH2
10 positive regulation of DNA repair GO:0045739 9.43 EGFR MGMT PCNA
11 spinal cord oligodendrocyte cell fate specification GO:0021530 9.4 NKX2-2 OLIG2
12 spinal cord oligodendrocyte cell differentiation GO:0021529 9.37 NKX2-2 OLIG2
13 glyoxylate cycle GO:0006097 9.16 IDH1 IDH2
14 positive regulation of oligodendrocyte differentiation GO:0048714 9.13 NKX2-2 OLIG2 TP73
15 response to organic cyclic compound GO:0014070 9.02 EGFR IDH1 MGMT NKX2-2 PTEN

Molecular functions related to Oligodendroglioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 EGFR GFAP PCNA PTEN SYP TP53
2 chromatin binding GO:0003682 9.77 EGFR NKX2-2 PCNA TP53 TP73
3 magnesium ion binding GO:0000287 9.73 ENO2 IDH1 IDH2 PTEN
4 damaged DNA binding GO:0003684 9.58 PCNA TP53 TP73
5 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.46 CDKN2A CDKN2C
6 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.16 IDH1 IDH2
7 protein kinase binding GO:0019901 9.1 CDKN2A CDKN2C EGFR PTEN TP53 TP73
8 isocitrate dehydrogenase activity GO:0004448 8.96 IDH1 IDH2
9 DNA binding GO:0003677 10.02 CDKN2A CIC MGMT NKX2-2 OLIG1 OLIG2

Sources for Oligodendroglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....